ACTIVATION OF BCR-ABL FUSION GENE AND RAS ONCOGENES IN CHRONIC MYELOGENOUS LEUKEMIA

被引:4
|
作者
FUTAKI, M
INOKUCHI, K
DAN, K
NOMURA, T
机构
[1] The Third Department of Internal Medicine, Nippon Medical School, Tokyo
关键词
CML; PHILADELPHIA CHROMOSOME; BCR-ABL FUSION GENE; TRANSFORMING; GENE; RAS ONCOGENES;
D O I
10.3109/10428199109068121
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We attempted to detect the bcr-abl fusion gene and ras gene family in CML by the in vitro focus forming assay and the tumorigenicity assay. Eight of 14 chronic phase and both of two blastic phase cases showed transforming activity in the tumorigenicity assay. However, only one chronic phase sample was positive in the in vitro focus forming assay. Among these 10 transformants, we found N-ras activation in one chronic phase, and K-ras activation in another chronic phase case. The bcr-abl fusion gene was activated in one chronic phase and all of the blastic phase cases by the tumorigenicity assay. The present result showed that the bcr-abl fusion gene transfected N1H3T3 cells formed tumors in nude mice in contrast to the in vitro focus forming assay. The bcr-abl fusion gene may play important roles in the progression as well as the pathogenesis of CML. © 1991 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.
引用
收藏
页码:163 / 169
页数:7
相关论文
共 50 条
  • [21] BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells
    Brauer, Katharina M.
    Werth, Daniela
    von Schwarzenberg, Karin
    Bringmann, Anita
    Kanz, Lothar
    Gruenebach, Frank
    Brossart, Peter
    CANCER RESEARCH, 2007, 67 (11) : 5489 - 5497
  • [22] The circulating dendritic cell compartment in chronic myelogenous leukemia patients is functional and expresses the bcr-abl fusion gene.
    Orsini, E
    Calabrese, E
    Nanni, M
    Guarini, A
    Foa, R
    BLOOD, 2002, 100 (11) : 370A - 370A
  • [23] Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia
    O'Dwyer, ME
    Druker, BJ
    CURRENT OPINION IN ONCOLOGY, 2000, 12 (06) : 594 - 597
  • [24] Mechanism of stability and degradation of the chronic myelogenous leukemia oncoprotein, BCR-ABL
    Tsukahara, F
    Maru, Y
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 94 : 105P - 105P
  • [25] The role of RAS effectors in BCR/ABL induced chronic myelogenous leukemia
    Jessica Fredericks
    Ruibao Ren
    Frontiers of Medicine, 2013, 7 : 452 - 461
  • [26] Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more
    Cea, M.
    Cagnetta, A.
    Garuti, A.
    Cirmena, G.
    Rocco, I.
    Moran, E.
    Grillo, V.
    Ballestrero, A.
    Patrone, F.
    Nencioni, A.
    JOURNAL OF BUON, 2009, 14 (04): : 565 - 573
  • [27] The role of RAS effectors in BCR/ABL induced chronic myelogenous leukemia
    Jessica Fredericks
    Ruibao Ren
    Frontiers of Medicine, 2013, 7 (04) : 452 - 461
  • [28] The role of RAS effectors in BCR/ABL induced chronic myelogenous leukemia
    Fredericks, Jessica
    Ken, Ruibao
    FRONTIERS OF MEDICINE, 2013, 7 (04) : 452 - 461
  • [29] ALTERNATIVE 5' END OF THE BCR-ABL TRANSCRIPT IN CHRONIC MYELOGENOUS LEUKEMIA
    ROMERO, P
    BERAN, M
    SHTALRID, M
    ANDERSSON, B
    TALPAZ, M
    BLICK, M
    ONCOGENE, 1989, 4 (01) : 93 - 98
  • [30] Clinical Significance of BCR-ABL Fusion Gene Subtypes in Chronic Myelogenous and Acute Lymphoblastic Leukemias
    Ye, Yuan-Xin
    Zhou, Juan
    Zhou, Yan-Hong
    Zhou, Yi
    Song, Xing-Bo
    Wang, Jun
    Lin, Li
    Ying, Bin-Wu
    Lu, Xiao-Jun
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (22) : 9961 - 9966